BXPHF (Botanix Pharmaceuticals) Total Liabilities: $29.62 Mil (As of Dec. 2025)


What is Botanix Pharmaceuticals Total Liabilities?

Botanix Pharmaceuticals BXPHF Total Liabilities is $29.62 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Botanix Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was $29.62 Mil.

Botanix Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2024 ($4.41 Mil) to Jun. 2025 ($31.12 Mil) but then declined from Jun. 2025 ($31.12 Mil) to Dec. 2025 ($29.62 Mil).

Botanix Pharmaceuticals's annual Total Liabilities increased from Jun. 2023 ($1.27 Mil) to Jun. 2024 ($2.48 Mil) and increased from Jun. 2024 ($2.48 Mil) to Jun. 2025 ($31.12 Mil).

Botanix Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Botanix Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Botanix Pharmaceuticals Total Liabilities Chart

Botanix Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 4.83 1.27 2.48 31.12

Botanix Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 2.48 4.41 31.12 29.62

Botanix Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Botanix Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16.225+(14.893+-0.0010000000000012
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=31.12

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=84.046-52.929
=31.12

Botanix Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.381+(11.239+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=29.62

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=65.497-35.877
=29.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $29.62 Mil mean?
Botanix Pharmaceuticals (BXPHF) has a Total Liabilities of $29.62 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Botanix Pharmaceuticals and its competitors.
Is Botanix Pharmaceuticals' Total Liabilities too high?
Botanix Pharmaceuticals' current Total Liabilities is $29.62 Mil.
How does Botanix Pharmaceuticals' Total Liabilities compare to VRTX and REGN?
Botanix Pharmaceuticals' Total Liabilities of $29.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Botanix Pharmaceuticals and its competitors. Botanix Pharmaceuticals's current Total Liabilities is $29.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (BXPHF) has a current Total Liabilities of $29.62 Mil. The current Total Liabilities is $29.62 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Botanix Pharmaceuticals (BXPHF), the current Total Liabilities is $29.62 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Botanix Pharmaceuticals Business Description

Other Exchanges BOT:Australia
Address 41 - 47 Colin Street, Suite 3, West Perth, WA, AUS, 6005
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.